492 results on '"Billington, Charles J."'
Search Results
2. Results From a Trial of an Online Diabetes Prevention Program Intervention
- Author
-
Moin, Tannaz, Damschroder, Laura J, AuYoung, Mona, Maciejewski, Matthew L, Havens, Kathryn, Ertl, Kristyn, Vasti, Elena, Weinreb, Jane E, Steinle, Nanette I, Billington, Charles J, Hughes, Maria, Makki, Fatima, Youles, Bradley, Holleman, Robert G, Kim, H Myra, Kinsinger, Linda S, and Richardson, Caroline R
- Subjects
Health Services and Systems ,Health Sciences ,Nutrition ,Diabetes ,Obesity ,Clinical Research ,Comparative Effectiveness Research ,Clinical Trials and Supportive Activities ,Health Services ,Prevention ,Prevention of disease and conditions ,and promotion of well-being ,3.1 Primary prevention interventions to modify behaviours or promote wellbeing ,Metabolic and endocrine ,Good Health and Well Being ,Aged ,Diabetes Mellitus ,Type 2 ,Female ,Humans ,Internet ,Male ,Middle Aged ,Overweight ,Prediabetic State ,United States ,United States Department of Veterans Affairs ,Veterans ,Weight Loss ,Weight Reduction Programs ,Medical and Health Sciences ,Education ,Public Health ,Biomedical and clinical sciences ,Health sciences - Abstract
IntroductionOnline Diabetes Prevention Programs (DPPs) can be scaled up and delivered broadly. However, little is known about real-world effectiveness and how outcomes compare with in-person DPP. This study examined online DPP weight loss and participation outcomes and secondarily compared outcomes among participating individuals with parallel in-person interventions.Study designA large non-randomized trial supplemented by a comparative analysis of participating individuals from a concurrent trial of two parallel in-person programs: in-person DPP and the Veterans Administration's standard of care weight loss program (MOVE!).Setting/participantsObese/overweight Veterans with prediabetes enrolled in online DPP (n = 268) between 2013 and 2014. Similar eligibility criteria were used to enroll in-person participants between 2012 and 2014 (n = 273 in-person DPP, n = 114 MOVE!) within a separate trial.InterventionOnline DPP included a virtual group format, live e-coach, weekly modules delivered asynchronously, and wireless home scales. In-person programs included eight to 22 group-based, face-to-face sessions.Main outcomes measuresWeight change at 6 and 12 months using wirelessly uploaded home scale data or electronic medical record weights from clinical in-person visits. Outcomes were analyzed between 2015 and 2017.ResultsFrom 1,182 invitations, 268 (23%) participants enrolled in online DPP. Among these, 158 (56%) completed eight or more modules; mean weight change was -4.7kg at 6 months and -4.0kg at 12 months. In a supplemental analysis of participants completing one or more sessions/modules, online DPP participants were most likely to complete eight or more sessions/modules (87% online DPP vs 59% in-person DPP vs 55% MOVE!, p
- Published
- 2018
3. A case of VEXAS syndrome associated with EBV-associated hemophagocytic lymphohistiocytosis
- Author
-
Kao, Roy L., Jacobsen, Audrey A., Billington, Charles J., Jr, Yohe, Sophia L., Beckman, Amy K., Vercellotti, Gregory M., and Pearson, David R.
- Published
- 2022
- Full Text
- View/download PDF
4. Matrisome and Immune Pathways Contribute to Extreme Vascular Outcomes in Williams–Beuren Syndrome
- Author
-
Liu, Delong, primary, Billington, Charles J., additional, Raja, Neelam, additional, Wong, Zoe C., additional, Levin, Mark D., additional, Resch, Wulfgang, additional, Alba, Camille, additional, Hupalo, Daniel N., additional, Biamino, Elisa, additional, Bedeschi, Maria Francesca, additional, Digilio, Maria Cristina, additional, Squeo, Gabriella Maria, additional, Villa, Roberta, additional, Parrish, Pheobe C. R., additional, Knutsen, Russell H., additional, Osgood, Sharon, additional, Freeman, Joy A., additional, Dalgard, Clifton L., additional, Merla, Giuseppe, additional, Pober, Barbara R., additional, Mervis, Carolyn B., additional, Roberts, Amy E., additional, Morris, Colleen A., additional, Osborne, Lucy R., additional, and Kozel, Beth A., additional
- Published
- 2024
- Full Text
- View/download PDF
5. Cost-Effectiveness of Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review of Cost-Effectiveness Studies for the American College of Physicians.
- Author
-
Schousboe, John T., Landsteiner, Adrienne, Drake, Tyler, Sultan, Shahnaz, Langsetmo, Lisa, Kaka, Anjum, Anthony, Maylen, Billington, Charles J., Kalinowski, Caleb, Ullman, Kristen, and Wilt, Timothy J.
- Subjects
TYPE 2 diabetes ,PHYSICIANS ,GASTRIC inhibitory polypeptide ,COST effectiveness ,GLUCAGON-like peptide-1 agonists - Abstract
This systematic review of cost-effectiveness analyses of newer antidiabetes medications for type 2 diabetes was done to inform the ACP clinical guideline on newer pharmacologic treatments in adults with type 2 diabetes. It evaluates the nonindustry-funded cost-effectiveness analyses that estimate the cost per quality-adjusted life-years gained for SGLT2 inhibitors, GLP1 agonists, DPP4 inhibitors, and long-acting insulins as monotherapy or combination therapy in treating adults with type 2 diabetes mellitus. Background: In the United States, costs of antidiabetes medications exceed $327 billion. Purpose: To systematically review cost-effectiveness analyses (CEAs) of newer antidiabetes medications for type 2 diabetes. Data Sources: Bibliographic databases from 1 January 2010 through 13 July 2023, limited to English. Study Selection: Nonindustry-funded CEAs, done from a U.S. perspective that estimated cost per quality-adjusted life-year (QALY) gained for newer antidiabetic medications. Two reviewers screened the literature; disagreements were resolved with a third reviewer. Data Extraction: Cost-effectiveness analyses were reviewed for treatment comparisons, model inputs, and outcomes. Risk of bias (RoB) of the CEAs was assessed using Drummond criteria and certainty of evidence (CoE) was assessed using GRADE (Grading of Recommendations Assessment, Development, and Evaluations). Certainty of evidence was determined using cost per QALY thresholds predetermined by the American College of Physicians Clinical Guidelines Committee; low (>$150 000), intermediate ($50 to $150 000), or high (<$50 000) value per QALY compared with the alternative. Data Synthesis: Nine CEAs were eligible (2 low, 1 high, and 6 some concerns RoB), evaluating glucagon-like peptide-1 agonists (GLP1a), dipeptidyl peptidase-4 inhibitors (DPP4i), sodium–glucose cotransporter-2 inhibitors (SGLT2i), glucose-dependent insulinotropic peptide agonist (GIP/GLP1a), and insulin. Comparators were metformin, sulfonylureas, neutral protamine Hagedorn (NPH) insulin, and others. Compared with metformin, GLP1a and SGLT2i are low value as first-line therapy (high CoE) but may be of intermediate value when added to metformin or background therapy compared with adding nothing (low CoE). Insulin analogues may be similarly effective but more expensive than NPH insulin (low CoE). The GIP/GLP1a value is uncertain (insufficient CoE). Limitations: Cost-effectiveness analyses varied in methodological approach, assumptions, and drug comparisons. Risk of bias and GRADE method for CEAs are not well established. Conclusion: Glucagon-like peptide-1 agonists and SGLT2i are of low value as first-line therapy but may be of intermediate value when added to metformin or other background therapy compared with adding nothing. Other drugs and comparisons are of low or uncertain value. Results are sensitive to drug effectiveness and cost assumptions. Primary Funding Source: American College of Physicians. (PROSPERO: CRD42022382315) [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review and Network Meta-analysis for the American College of Physicians.
- Author
-
Drake, Tyler, Landsteiner, Adrienne, Langsetmo, Lisa, MacDonald, Roderick, Anthony, Maylen, Kalinowski, Caleb, Ullman, Kristen, Billington, Charles J., Kaka, Anjum, Sultan, Shahnaz, and Wilt, Timothy J.
- Subjects
TYPE 2 diabetes ,PHYSICIANS ,MAJOR adverse cardiovascular events ,SODIUM-glucose cotransporter 2 inhibitors ,ADULTS - Abstract
This systematic review on the effect of newer diabetes medications on mortality, cardiovascular outcomes, and renal outcomes was conducted to inform the ACP clinical guideline on newer pharmacologic treatments in adults with type 2 diabetes mellitus. It evaluates the effectiveness, comparative effectiveness, and harms of sodium–glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP1) agonists, dipeptidyl peptidase-4 (DPP4) inhibitors, and long-acting insulins as monotherapy or combination therapy in treating adults with type 2 diabetes mellitus. Background: Newer diabetes medications may have beneficial effects on mortality, cardiovascular outcomes, and renal outcomes. Purpose: To evaluate the effectiveness, comparative effectiveness, and harms of sodium–glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP1) agonists, dipeptidyl peptidase-4 (DPP4) inhibitors, and long-acting insulins as monotherapy or combination therapy in adults with type 2 diabetes mellitus (T2DM). Data Sources: MEDLINE and EMBASE for randomized controlled trials (RCTs) published from 2010 through January 2023. Study Selection: RCTs lasting at least 52 weeks that included at least 500 adults with T2DM receiving eligible medications and reported any outcomes of interest. Data Extraction: Data were abstracted by 1 reviewer and verified by a second. Independent, dual assessments of risk of bias and certainty of evidence (CoE) were done. Data Synthesis: A total of 130 publications from 84 RCTs were identified. CoE was appraised using GRADE (Grading of Recommendations Assessment, Development and Evaluation) criteria for direct, indirect, and network meta-analysis (NMA); the highest CoE was reported. Compared with usual care, SGLT2 inhibitors and GLP1 agonists reduce all-cause mortality (high CoE) and major adverse cardiovascular events (MACE) (moderate to high CoE), SGLT2 inhibitors reduce progression of chronic kidney disease (CKD) and heart failure hospitalizations and GLP1 agonists reduce stroke (high CoE), and SGLT2 inhibitors reduce serious adverse events and severe hypoglycemia (high CoE). The threshold for minimally important differences, which was predefined with the American College of Physicians Clinical Guidelines Committee, was not met for these outcomes. Compared with usual care, insulin, tirzepatide, and DPP4 inhibitors do not reduce all-cause mortality (low to high CoE). Compared with insulin, SGLT2 inhibitors and GLP1 agonists reduce all-cause mortality (low to moderate CoE). Compared with DPP4 inhibitors, GLP1 agonists reduce all-cause mortality (moderate CoE). Compared with DPP4 inhibitors and sulfonylurea (SU), SGLT2 inhibitors reduce MACE (moderate to high CoE). Compared with SU and insulin, SGLT2 inhibitors and GLP1 agonists reduce severe hypoglycemia (low to high CoE). Limitations: Infrequent direct comparisons between drugs of interest; sparse data for NMA on most outcomes; possible incoherence due to differences in baseline patient characteristics and usual care; insufficient data on predefined subgroups, including demographic subgroups, patients with prior cardiovascular disease, and treatment-naive persons. Conclusion: In adults with T2DM, SGLT2 inhibitors and GLP1 agonists (but not DPP4 inhibitors, insulin, or tirzepatide) reduce all-cause mortality and MACE compared with usual care. SGLT2 inhibitors reduce CKD progression and heart failure hospitalization and GLP1 agonists reduce stroke compared with usual care. Serious adverse events and severe hypoglycemia are less frequent with SGLT2 inhibitors and GLP1 agonists than with insulin or SU. Primary Funding Source: American College of Physicians. (PROSPERO: CRD42022322129) [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Telephone Virtual Versus In-Person Pharmacotherapy-Based Obesity Care: A COVID-19-Related Experience at a Veterans Administration Facility.
- Author
-
Kaur, Jasleen, Lee, Yee L., Stortz, Ethan, Palani, Guru, Elkin, Baila, Gravely, Amy, Westanmo, Anders, Billington, Charles J., Ercan-Fang, Nacide, and Sibley, Shalamar D.
- Subjects
OBESITY ,COUPLES counseling ,VETERANS ,REGULATION of body weight ,TELEPHONES ,NURSE practitioners - Abstract
Background:Most of the Veterans Administration (VA) population is either overweight or obese, which is a serious health concern. Medical weight management visits have traditionally occurred through in-person clinics. However, the COVID-19 pandemic forced care delivery to virtual platforms. Methods:We compared weight loss with in-person versus telephone-based medical weight management (lifestyle counseling coupled with pharmacotherapy) delivered by physician and nurse practitioner visits during the pandemic. We designed a program evaluation utilizing a naturalistic (pragmatic) observational study structure, including both newly enrolled and previously established participants in the Minneapolis VA MOVE! program between 2017 and 2021. A "transition" cohort (n = 74) received in-person care from March 2019 to March 2020, and then transitioned to virtual care. A "new start" virtual care cohort (n = 149) enrolled after March 2020 was compared to a separate historical group (n = 180) that received in-person care between January 2017 and December 2019. Weight loss was accessed over a 9-month period in both cohorts. Results:Mean weight loss over 9 months was −6.5 ± 18.2 and −2.5 ± 13.3 lbs in the in-person and virtual phases of the transition cohort, respectively, without significant difference between the two phases (p = 0.22). Mean weight loss over 9 months in the new start (virtual) cohort was −14.4 ± 17.0 lbs compared to −16.7 ± 21.0 lbs in the historical cohort, without significant difference between groups (p = 0.44). Conclusions:In our naturalistic study in a single-site VA clinic setting, weight loss with telephone-based medical weight management during the pandemic was comparable to in-person care. These findings are important for veterans living in rural and/or underserved areas. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Implementation and evaluation of the VA DPP clinical demonstration: protocol for a multi-site non-randomized hybrid effectiveness-implementation type III trial
- Author
-
Damschroder, Laura J, Moin, Tannaz, Datta, Santanu K, Reardon, Caitlin M, Steinle, Nanette, Weinreb, Jane, Billington, Charles J, Maciejewski, Matt L, Yancy, William S, Hughes, Maria, Makki, Fatima, and Richardson, Caroline R
- Subjects
Biomedical and Clinical Sciences ,Psychology ,Obesity ,Clinical Trials and Supportive Activities ,Diabetes ,Clinical Research ,Comparative Effectiveness Research ,Nutrition ,Prevention ,Cost Effectiveness Research ,Metabolic and endocrine ,Good Health and Well Being ,Body Weight ,Cost-Benefit Analysis ,Diabetes Mellitus ,Type 2 ,Evidence-Based Medicine ,Female ,Glycated Hemoglobin ,Health Behavior ,Health Promotion ,Humans ,Life Style ,Male ,Research Design ,United States ,United States Department of Veterans Affairs ,Diabetes prevention ,Implementation ,Veterans ,Pragmatic study design ,Information and Computing Sciences ,Medical and Health Sciences ,Health Policy & Services ,Biomedical and clinical sciences - Abstract
BackgroundThe Diabetes Prevention Program (DPP) study showed that lifestyle intervention resulted in a 58% reduction in incidence of type 2 diabetes among individuals with prediabetes. Additional large randomized controlled trials have confirmed these results, and long-term follow-up has shown sustained benefit 10-20 years after the interventions ended. Diabetes is a common and costly disease, especially among Veterans, and despite strong evidence supporting the feasibility of type 2 diabetes prevention, the DPP has not been widely implemented. The first aim of this study will evaluate implementation of the Veterans Affairs (VA) DPP in three VA medical centers. The second aim will assess weight and hemoglobin A1c (A1c) outcomes, and the third aim will determine the cost-effectiveness and budget impact of implementation of the VA DPP from a health system perspective.Methods/designThis partnered multi-site non-randomized systematic assignment study will use a highly pragmatic hybrid effectiveness-implementation type III mixed methods study design. The implementation and administration of the VA DPP will be funded by clinical operations while the evaluation of the VA DPP will be funded by research grants. Seven hundred twenty eligible Veterans will be systematically assigned to the VA DPP clinical demonstration or the usual care VA MOVE!® weight management program. A multi-phase formative evaluation of the VA DPP implementation will be conducted. A theoretical program change model will be used to guide the implementation process and assess applicability and feasibility of the DPP for VA. The Consolidated Framework for Implementation Research (CFIR) will be used to guide qualitative data collection, analysis, and interpretation of barriers and facilitators to implementation. The RE-AIM framework will be used to assess Reach, Effectiveness, Adoption, Implementation, and Maintenance of the VA DPP. Twelve-month weight and A1c change will be evaluated for the VA DPP compared to the VA MOVE!ProgramMediation analyses will be conducted to identify whether program design differences impact outcomes.DiscussionFindings from this pragmatic evaluation will be highly applicable to practitioners who are tasked with implementing the DPP in clinical settings. In addition, findings will determine the effectiveness and cost-effectiveness of the VA DPP in the Veteran population.
- Published
- 2015
9. Serum FABP4 concentrations decrease after Roux-en-Y gastric bypass but not after intensive medical management
- Author
-
Jahansouz, Cyrus, Xu, Hongliang, Kizy, Scott, Thomas, Avis J., Josephrajan, Ajeetha, Hertzel, Ann V., Foncea, Rocio, Connett, John C., Billington, Charles J., Jensen, Michael, Korner, Judith, Bernlohr, David A., and Ikramuddin, Sayeed
- Published
- 2019
- Full Text
- View/download PDF
10. Combining Celiac and Hepatic Vagus Nerve Neuromodulation Reverses Glucose Intolerance and Improves Glycemic Control in Pre- and Overt-Type 2 Diabetes Mellitus
- Author
-
Waataja, Jonathan J., primary, Asp, Anders J., additional, and Billington, Charles J., additional
- Published
- 2023
- Full Text
- View/download PDF
11. Orexin/hypocretin treatment restores hippocampal-dependent memory in orexin-deficient mice
- Author
-
Mavanji, Vijayakumar, Butterick, Tammy A., Duffy, Cayla M., Nixon, Joshua P., Billington, Charles J., and Kotz, Catherine M.
- Published
- 2017
- Full Text
- View/download PDF
12. Spontaneous Physical Activity Defends Against Obesity
- Author
-
Kotz, Catherine M., Perez-Leighton, Claudio E., Teske, Jennifer A., and Billington, Charles J.
- Published
- 2017
- Full Text
- View/download PDF
13. Roux-en-Y gastric bypass for diabetes (the Diabetes Surgery Study): 2-year outcomes of a 5-year, randomised, controlled trial
- Author
-
Ikramuddin, Sayeed, Billington, Charles J, Lee, Wei-Jei, Bantle, John P, Thomas, Avis J, Connett, John E, Leslie, Daniel B, Inabnet, William B, III, Jeffery, Robert W, Chong, Keong, Chuang, Lee-Ming, Sarr, Michael G, Jensen, Michael D, Vella, Adrian, Ahmed, Leaque, Belani, Kumar, Schone, Joyce L, Olofson, Amy E, Bainbridge, Heather A, Laqua, Patricia S, Wang, Qi, and Korner, Judith
- Published
- 2015
- Full Text
- View/download PDF
14. Reporting of Incidental Thyroid Nodules on Chest Computed Tomography and the Impact on Nodule Evaluation: A Retrospective Cohort Study
- Author
-
Drake, Tyler, primary, Gravely, Amy, additional, Ensrud, Kristine, additional, and Billington, Charles J., additional
- Published
- 2022
- Full Text
- View/download PDF
15. Use of a bio-electronic device comprising of targeted dual neuromodulation of the hepatic and celiac vagal branches demonstrated enhanced glycemic control in a type 2 diabetic rat model as well as in an Alloxan treated swine model
- Author
-
Waataja, Jonathan J., primary, Nihalani, Raj K., additional, Honda, Chris N., additional, and Billington, Charles J., additional
- Published
- 2022
- Full Text
- View/download PDF
16. National Differences in Remission of Type 2 Diabetes Mellitus After Roux-en-Y Gastric Bypass Surgery-Subgroup Analysis of 2-Year Results of the Diabetes Surgery Study Comparing Taiwanese with Americans with Mild Obesity (BMI 30–35 kg/m2)
- Author
-
Chong, Keong, Ikramuddin, Sayeed, Lee, Wei-Jei, Billington, Charles J., Bantle, John P., Wang, Qi, Thomas, Avis J., Connett, John E., Leslie, Daniel B., Inabnet, III, William B., Jeffery, Robert W., Sarr, Michael G., Jensen, Michael D., Vella, Adrian, Ahmed, Leaque, Belani, Kumar, Schone, Joyce L., Olofson, Amy E., Bainbridge, Heather A., Laqua, Patricia S., Korner, Judith, and Chuang, Lee-Ming
- Published
- 2017
- Full Text
- View/download PDF
17. Two-Year Outcomes of Vagal Nerve Blocking (vBloc) for the Treatment of Obesity in the ReCharge Trial
- Author
-
Apovian, Caroline M., Shah, Sajani N., Wolfe, Bruce M., Ikramuddin, Sayeed, Miller, Christopher J., Tweden, Katherine S., Billington, Charles J., and Shikora, Scott A.
- Published
- 2017
- Full Text
- View/download PDF
18. Exercise reduces diet-induced cognitive decline and increases hippocampal brain-derived neurotrophic factor in CA3 neurons
- Author
-
Noble, Emily E., Mavanji, Vijayakumar, Little, Morgan R., Billington, Charles J., Kotz, Catherine M., and Wang, ChuanFeng
- Published
- 2014
- Full Text
- View/download PDF
19. Neuropeptides Controlling Energy Balance: Orexins and Neuromedins
- Author
-
Nixon, Joshua P., Kotz, Catherine M., Novak, Colleen M., Billington, Charles J., Teske, Jennifer A., and Joost, Hans-Georg, editor
- Published
- 2012
- Full Text
- View/download PDF
20. COVID-19 postacute care major organ damage: a systematic review
- Author
-
Greer, Nancy, primary, Bart, Bradley, additional, Billington, Charles J, additional, Diem, Susan J, additional, Ensrud, Kristine E, additional, Kaka, Anjum, additional, Klein, Mark, additional, Melzer, Anne C, additional, Reule, Scott, additional, Shaukat, Aasma, additional, Sheets, Kerry, additional, Starks, Jamie, additional, Vardeny, Orly, additional, McKenzie, Lauren, additional, Stroebel, Benjamin, additional, Macdonald, Roderick, additional, Sowerby, Katie, additional, Duan-Porter, Wei, additional, and Wilt, Timothy J, additional
- Published
- 2022
- Full Text
- View/download PDF
21. Genomic and biochemical analysis of repeatedly observed variants inDBTin individuals with maple syrup urine disease of Central American ancestry
- Author
-
Billington, Charles J., primary, Chapman, Kimberly A., additional, Leon, Eyby, additional, Meltzer, Beatrix W., additional, Berger, Seth I., additional, Olson, Matthew, additional, Figler, Robert A., additional, Hoang, Steve A., additional, Wanxing, Cui, additional, Wamhoff, Brian R., additional, Collado, M. Sol, additional, and Cusmano‐Ozog, Kristina, additional
- Published
- 2022
- Full Text
- View/download PDF
22. Lifestyle Intervention and Medical Management With vs Without Roux-en-Y Gastric Bypass and Control of Hemoglobin A1c, LDL Cholesterol, and Systolic Blood Pressure at 5 Years in the Diabetes Surgery Study
- Author
-
Ikramuddin, Sayeed, Korner, Judith, Lee, Wei-Jei, Thomas, Avis J., Connett, John E., Bantle, John P., Leslie, Daniel B., Wang, Qi, Inabnet, William B., III, Jeffery, Robert W., Chong, Keong, Chuang, Lee-Ming, Jensen, Michael D., Vella, Adrian, Ahmed, Leaque, Belani, Kumar, and Billington, Charles J.
- Published
- 2018
- Full Text
- View/download PDF
23. Effect of Vagal Nerve Blockade on Moderate Obesity with an Obesity-Related Comorbid Condition: the ReCharge Study
- Author
-
Morton, John M., Shah, Sajani N., Wolfe, Bruce M., Apovian, Caroline M., Miller, Christopher J., Tweden, Katherine S., Billington, Charles J., and Shikora, Scott A.
- Published
- 2016
- Full Text
- View/download PDF
24. Monoallelic and biallelic mutations in RELN underlie a graded series of neurodevelopmental disorders
- Author
-
Di Donato, Nataliya, primary, Guerrini, Renzo, additional, Billington, Charles J, additional, Barkovich, A James, additional, Dinkel, Philine, additional, Freri, Elena, additional, Heide, Michael, additional, Gershon, Elliot S, additional, Gertler, Tracy S, additional, Hopkin, Robert J, additional, Jacob, Suma, additional, Keedy, Sarah K, additional, Kooshavar, Daniz, additional, Lockhart, Paul J, additional, Lohmann, Dietmar R, additional, Mahmoud, Iman G, additional, Parrini, Elena, additional, Schrock, Evelin, additional, Severi, Giulia, additional, Timms, Andrew E, additional, Webster, Richard I, additional, Willis, Mary J H, additional, Zaki, Maha S, additional, Gleeson, Joseph G, additional, Leventer, Richard J, additional, and Dobyns, William B, additional
- Published
- 2022
- Full Text
- View/download PDF
25. Copper-Binding Domain Variation in a Novel Murine Lysyl Oxidase Model Produces Structurally Inferior Aortic Elastic Fibers Whose Failure Is Modified by Age, Sex, and Blood Pressure
- Author
-
Tsang, Kit Man, primary, Knutsen, Russell H., additional, Billington, Charles J., additional, Lindberg, Eric, additional, Steenbock, Heiko, additional, Fu, Yi-Ping, additional, Wardlaw-Pickett, Amanda, additional, Liu, Delong, additional, Malide, Daniela, additional, Yu, Zu-Xi, additional, Bleck, Christopher K. E., additional, Brinckmann, Jürgen, additional, and Kozel, Beth A., additional
- Published
- 2022
- Full Text
- View/download PDF
26. Exenatide for weight‐loss maintenance in adolescents with severe obesity: A randomized, placebo‐controlled trial
- Author
-
Fox, Claudia K., primary, Clark, Justin M., additional, Rudser, Kyle D., additional, Ryder, Justin R., additional, Gross, Amy C., additional, Nathan, Brandon M., additional, Sunni, Muna, additional, Dengel, Donald R., additional, Billington, Charles J., additional, Bensignor, Megan O., additional, and Kelly, Aaron S., additional
- Published
- 2022
- Full Text
- View/download PDF
27. Frequency of QTc Interval Prolongation in Children and Adults with Williams Syndrome
- Author
-
Brink, Benjamin D., primary, Feinn, Richard, additional, Kozel, Beth A., additional, Billington, Charles J., additional, Liu, Delong, additional, Yu, Eric, additional, Sindhar, Sampat, additional, He, Julie, additional, Rouse, Charles, additional, Lampert, Rachel, additional, Pober, Barbara R., additional, and Elder, Robert W., additional
- Published
- 2022
- Full Text
- View/download PDF
28. Sleep and obesity: A focus on animal models
- Author
-
Mavanji, Vijayakumar, Billington, Charles J., M. Kotz, Catherine, and Teske, Jennifer A.
- Published
- 2012
- Full Text
- View/download PDF
29. A Randomized Trial Comparing Roux-en-Y Gastric Bypass to Intensive Medical Management in Obese Patients with Type 2 Diabetes Mellitus
- Author
-
Connett, John E., Ikramuddin, Sayeed, Thomas, Avis J., Bantle, John P., Billington, Charles J., Chong, Keong, Chuang, Lee-Ming, Inabnet, William B., III, Jeffery, Robert W., Korner, Judith, Laqua, Patricia S., Lee, Wei-Jei, and Leslie, Daniel B.
- Published
- 2012
- Full Text
- View/download PDF
30. Rare presentation of FDX2‐related disorder and untargeted global metabolomics findings
- Author
-
Aggarwal, Anjali, primary, Pillai, Nishitha R., additional, Billington, Charles J., additional, Schema, Lynn, additional, and Berry, Susan A., additional
- Published
- 2021
- Full Text
- View/download PDF
31. Severe hyperammonemia in chimeric antigen receptor T cells recipient—unusual differential diagnosis of encephalopathy syndrome
- Author
-
Sumransub, Nuttavut, primary, He, Fiona, additional, Weisdorf, Daniel, additional, Billington, Charles J., additional, Aggarwal, Anjali, additional, Miller, Benjamin, additional, and Bachanova, Veronika, additional
- Published
- 2021
- Full Text
- View/download PDF
32. Orexin: Pathways to obesity resistance?
- Author
-
Butterick, Tammy A., Billington, Charles J., Kotz, Catherine M., and Nixon, Joshua P.
- Published
- 2013
- Full Text
- View/download PDF
33. Preserved Insulin Secretory Capacity and Weight Loss Are the Predominant Predictors of Glycemic Control in Patients With Type 2 Diabetes Randomized to Roux-en-Y Gastric Bypass
- Author
-
Nguyen, Kim T., Billington, Charles J., Vella, Adrian, Wang, Qi, Ahmed, Leaque, Bantle, John P., Bessler, Marc, Connett, John E., Inabnet, William B., Thomas, Avis, Ikramuddin, Sayeed, and Korner, Judith
- Published
- 2015
- Full Text
- View/download PDF
34. Selection of electrical algorithms to treat obesity with intermittent vagal block using an implantable medical device
- Author
-
Camilleri, Michael, Toouli, James, Herrera, Miguel F., Kow, Lilian, Pantoja, Juan Pablo, Billington, Charles J., Tweden, Katherine S., Wilson, Richard R., and Moody, Frank G.
- Published
- 2009
- Full Text
- View/download PDF
35. Monoallelic and biallelic mutations in RELN underlie a graded series of neurodevelopmental disorders.
- Author
-
Donato, Nataliya Di, Guerrini, Renzo, Billington, Charles J, Barkovich, A James, Dinkel, Philine, Freri, Elena, Heide, Michael, Gershon, Elliot S, Gertler, Tracy S, Hopkin, Robert J, Jacob, Suma, Keedy, Sarah K, Kooshavar, Daniz, Lockhart, Paul J, Lohmann, Dietmar R, Mahmoud, Iman G, Parrini, Elena, Schrock, Evelin, Severi, Giulia, and Timms, Andrew E
- Abstract
Reelin, a large extracellular protein, plays several critical roles in brain development and function. It is encoded by RELN , first identified as the gene disrupted in the reeler mouse, a classic neurological mutant exhibiting ataxia, tremors and a 'reeling' gait. In humans, biallelic variants in RELN have been associated with a recessive lissencephaly variant with cerebellar hypoplasia, which matches well with the homozygous mouse mutant that has abnormal cortical structure, small hippocampi and severe cerebellar hypoplasia. Despite the large size of the gene, only 11 individuals with RELN -related lissencephaly with cerebellar hypoplasia from six families have previously been reported. Heterozygous carriers in these families were briefly reported as unaffected, although putative loss-of-function variants are practically absent in the population (probability of loss of function intolerance = 1). Here we present data on seven individuals from four families with biallelic and 13 individuals from seven families with monoallelic (heterozygous) variants of RELN and frontotemporal or temporal-predominant lissencephaly variant. Some individuals with monoallelic variants have moderate frontotemporal lissencephaly, but with normal cerebellar structure and intellectual disability with severe behavioural dysfunction. However, one adult had abnormal MRI with normal intelligence and neurological profile. Thorough literature analysis supports a causal role for monoallelic RELN variants in four seemingly distinct phenotypes including frontotemporal lissencephaly, epilepsy, autism and probably schizophrenia. Notably, we observed a significantly higher proportion of loss-of-function variants in the biallelic compared to the monoallelic cohort, where the variant spectrum included missense and splice-site variants. We assessed the impact of two canonical splice-site variants observed as biallelic or monoallelic variants in individuals with moderately affected or normal cerebellum and demonstrated exon skipping causing in-frame loss of 46 or 52 amino acids in the central RELN domain. Previously reported functional studies demonstrated severe reduction in overall RELN secretion caused by heterozygous missense variants p.Cys539Arg and p.Arg3207Cys associated with lissencephaly suggesting a dominant-negative effect. We conclude that biallelic variants resulting in complete absence of RELN expression are associated with a consistent and severe phenotype that includes cerebellar hypoplasia. However, reduced expression of RELN remains sufficient to maintain nearly normal cerebellar structure. Monoallelic variants are associated with incomplete penetrance and variable expressivity even within the same family and may have dominant-negative effects. Reduced RELN secretion in heterozygous individuals affects only cortical structure whereas the cerebellum remains intact. Our data expand the spectrum of RELN -related neurodevelopmental disorders ranging from lethal brain malformations to adult phenotypes with normal brain imaging. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
36. Genomic and biochemical analysis of repeatedly observed variants in DBT in individuals with maple syrup urine disease of Central American ancestry.
- Author
-
Billington, Charles J., Chapman, Kimberly A., Leon, Eyby, Meltzer, Beatrix W., Berger, Seth I., Olson, Matthew, Figler, Robert A., Hoang, Steve A., Wanxing, Cui, Wamhoff, Brian R., Collado, M. Sol, and Cusmano‐Ozog, Kristina
- Abstract
Maple syrup urine disease (MSUD) is an intoxication‐type inherited metabolic disorder in which hyperleucinemia leads to brain swelling and death without treatment. MSUD is caused by branched‐chain alpha‐ketoacid dehydrogenase deficiency due to biallelic loss of the protein products from the genes BCKDHA, BCKDHB, or DBT, while a distinct but related condition is caused by loss of DLD. In this case series, eleven individuals with MSUD caused by two pathogenic variants in DBT are presented. All eleven individuals have a deletion of exon 2 (delEx2, NM_001918.3:c.48_171del); six individuals are homozygous and five individuals are compound heterozygous with a novel missense variant (NM_001918.5:c.916 T > C [p.Ser306Pro]) confirmed to be in trans. Western Blot indicates decreased amount of protein product in delEx2;c.916 T > C liver cells and absence of protein product in delEx2 homozygous hepatocytes. Ultrahigh performance liquid chromatography–tandem mass spectrometry demonstrates an accumulation of branched‐chain amino acids and alpha‐ketoacids in explanted hepatocytes. Individuals with these variants have a neonatal‐onset, non‐thiamine‐responsive, classical form of MSUD. Strikingly, the entire cohort is derived from families who immigrated to the Washington, DC, metro area from Honduras or El Salvador suggesting the possibility of a founder effect. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
37. The EMPOWER Study: Randomized, Prospective, Double-Blind, Multicenter Trial of Vagal Blockade to Induce Weight Loss in Morbid Obesity
- Author
-
Sarr, Michael G., Billington, Charles J., Brancatisano, Roy, Brancatisano, Anthony, Toouli, James, Kow, Lilian, Nguyen, Ninh T., Blackstone, Robin, Maher, James W., Shikora, Scott, Reeds, Dominic N., Eagon, J. Christopher, Wolfe, Bruce M., O’Rourke, Robert W., Fujioka, Ken, Takata, Mark, Swain, James M., Morton, John M., Ikramuddin, Sayeed, Schweitzer, Michael, Chand, Bipan, Rosenthal, Raul, and The EMPOWER Study Group
- Published
- 2012
- Full Text
- View/download PDF
38. Chronic administration of brain-derived neurotrophic factor in the hypothalamic paraventricular nucleus reverses obesity induced by high-fat diet
- Author
-
Wang, ChuanFeng, Godar, Rebecca J., Billington, Charles J., and Kotz, Catherine M.
- Subjects
Adipose tissues -- Health aspects ,Brain-derived neurotrophic factor -- Health aspects ,Obesity -- Care and treatment ,Obesity -- Research ,Biological sciences - Abstract
An acute injection of brain-derived neurotrophic factor (BDNF) in the hypothalamic paraventricular nucleus (PVN) reduces body weight by decreasing feeding and increasing energy expenditure (EE), in animals on standard laboratory chow. Animals have divergent responses to a high-fat diet (HFD) exposure, with some developing obesity and others remaining lean. In the current study, we tested two hypotheses: 1) BDNF in the PVN reverses HFD-induced obesity, and 2) animals with higher body fat have a greater physiological response to BDNF than those with less body fat. Eighty-four 10-wk old rats were allowed HFD ad libitum for 9 wk and then prepared with bilateral PVN cannulas. Animals were then divided into tertiles based on their body fat rank: high, intermediate, and low (H, I, and L). Each group was further divided into 2 subgroups and then PVN injected with BDNF or control (artificial cerebrospinal fluid, aCSF) every other day for 3 wk. Energy intake (EI), body weight, and body composition were measured. At study's end, rats were killed to allow measurement of other metabolic indices. In parallel, another 12 rats were fed control diet (CD), PVN-cannulated and injected with aCSF. HFD exposure induced obesity, particularly in the H body fat group, with a significant increase in El, body weight, fat mass, liver size, and serum glucose, triglycerides, insulin, and leptin. BDNF significantly reduced El, body weight, body fat, lean mass, and serum metabolic indices. These BDNF effects were greatest in the H body fat group. These data indicate that BDNF reduced HFD-induced obesity and metabolic syndrome-like measures, and the animals with the most body fat had the most significant response to BDNF. energy intake; body fat; metabolic syndrome doi: 10.1152/ajpregu.00844.2009.
- Published
- 2010
39. Effect of Reversible Intermittent Intra-abdominal Vagal Nerve Blockade on Morbid Obesity: The ReCharge Randomized Clinical Trial
- Author
-
Ikramuddin, Sayeed, Blackstone, Robin P., Brancatisano, Anthony, Toouli, James, Shah, Sajani N., Wolfe, Bruce M., Fujioka, Ken, Maher, James W., Swain, James, Que, Florencia G., Morton, John M., Leslie, Daniel B., Brancatisano, Roy, Kow, Lilian, O’Rourke, Robert W., Deveney, Clifford, Takata, Mark, Miller, Christopher J., Knudson, Mark B., Tweden, Katherine S., Shikora, Scott A., Sarr, Michael G., and Billington, Charles J.
- Published
- 2014
- Full Text
- View/download PDF
40. Rare presentation of FDX2‐related disorder and untargeted global metabolomics findings.
- Author
-
Aggarwal, Anjali, Pillai, Nishitha R., Billington, Charles J., Schema, Lynn, and Berry, Susan A.
- Abstract
We present the case of a 20‐year‐old male with a history of myopathy and multiple episodes of rhabdomyolysis, and lactic acidosis. He needed hemodialysis for severe rhabdomyolysis‐related acute renal failure at the time of initial presentation (age 10 years). Exome sequencing detected a homozygous likely pathogenic variant in FDX2 (c.12G>T, p.M4I). The FDX2 gene encodes a mitochondrial protein, ferredoxin 2, that is involved in the biogenesis of Fe–S clusters. Biallelic pathogenic variants in FDX2 have previously been associated with episodic mitochondrial myopathy with or without optic atrophy and reversible leukoencephalopathy. Only two cases with FDX2‐related rhabdomyolysis as a predominant feature have been reported in medical literature. Here, we report a third patient with FDX2‐related recurrent, severe episodes of rhabdomyolysis and lactic acidosis. He does not have optic atrophy or leukoencephalopathy. This is the oldest patient reported with FDX2‐related disorder and he has significantly elevated CK during episodes of rhabdomyolysis. In addition, we describe untargeted global metabolomic findings during an episode of metabolic decompensation, shedding light on the biochemical pathway perturbation associated with this ultra‐rare genetic disorder. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
41. Neuroregulation of nonexercise activity thermogenesis and obesity resistance
- Author
-
Kotz, Catherine M., Teske, Jennifer A., and Billington, Charles J.
- Subjects
Exercise -- Health aspects ,Obesity -- Prevention ,Thermogenesis -- Health aspects ,Biological sciences - Abstract
High levels of spontaneous physical activity in lean people and the nonexercise activity thermogenesis (NEAT) derived from that activity appear to protect lean people from obesity during caloric challenge, while obesity in humans is characterized by dramatically reduced spontaneous physical activity. We have similarly demonstrated that obesity-resistant rats have significantly greater spontaneous physical activity than obesity-prone rats, and that spontaneous physical activity predicts body weight gain. Although the energetic cost of activity varies between types of activity and may be regulated, individual level of spontaneous physical activity is important in determining propensity for obesity. We review the current status of knowledge about the brain mechanisms involved in controlling the level of spontaneous physical activity and the NEAT so generated. Focus is on potential neural mediators of spontaneous physical activity and NEAT, including orexin A (also known as hypocretin 1), agouti-related protein, ghrelin, and neuromedin U, in addition to brief mention of neuropeptide Y, corticotrophin releasing hormone, cholecystokinin, estrogen, leptin, and dopamine effects on spontaneous physical activity. We further review evidence that strain differences in orexin stimulation pathways for spontaneous physical activity and NEAT appear to track with the body weight phenotype, thus providing a potential mechanistic explanation for reduced activity and weight gain. spontaneous physical activity; energy expenditure; orexin; neuromedin U; ghrelin; agouti-related protein
- Published
- 2008
42. Paraventricular opioids alter intake of high-fat but not high-sucrose diet depending on diet preference in a binge model of feeding
- Author
-
Naleid, Amy M., Grace, Martha K., Chimukangara, Munya, Billington, Charles J., and Levine, Allen S.
- Subjects
Eating disorders -- Research ,Weight reducing preparations -- Research ,Obesity -- Research ,Neurological research ,Biological sciences - Abstract
Previous work from our laboratory indicates that when rats are given a choice between a high-fat and a high-sucrose diet, opioid blockade with naltrexone (NTX) in a reward-related site (central amygdala) inhibits intake of the preferred diet only, whereas NTX injected into a homeostasis-related site, such as the hypothalamic paraventricular nucleus (PVN), inhibits intake of both diets. However, other work suggests that opioids increase intake of fat specifically. The present study further investigates the role of PVN opioids in food choices made by calorically-replete animals. We used a binge model with chow-maintained rats given 3-h access to a choice of a high-fat or high-sucrose diet 3 days a week. We hypothesized that intra-PVN injection of the [micro]-opioid agonist, DAMGO (0, 0.025, 0.25, and 2.5 nmol) would enhance, and NTX (0, 10, 30, and 100 nmol) would inhibit intake of both diets to an equal extent. We found that when animals were divided into groups according to sucrose or fat preference, DAMGO increased fat intake in fat-consuming animals, while having no effect on intake of either diet in sucrose-consuming animals. NTX, however, inhibited fat intake in both groups. Intra-PVN NTX did not inhibit intake of sucrose when presented in the absence of a fat choice, but did so when injected peripherally. Furthermore, intra-PVN and systemic NTX inhibited intake of chow by 24-h-fooddeprived animals. These results indicate a complex role for PVN opioids in food intake with preference, nutrient type, and energy state affecting the ability of these compounds to change behavior. paraventricular nucleus; choice; palatability; reward; naltrexone; DAMGO doi:10.1152/ajpregu.00675.2006
- Published
- 2007
43. Opioids
- Author
-
Gosnell, Blake A., primary, Kotz, Catherine M., additional, Billington, Charles J., additional, and Levine, Allen S., additional
- Published
- 2013
- Full Text
- View/download PDF
44. Contributors
- Author
-
Aalen, Reidunn B., primary, Abdel-Wahab, Yasser H.A., additional, Adams, Michael E., additional, Adan, Roger A.H., additional, Ahima, Rexford S., additional, Ahmed, Naima, additional, Al-Massadi, Omar, additional, Altstein, Miriam, additional, Anouar, Youssef, additional, Anselmi, Laura, additional, Ansorge, Siegfried, additional, Antcheva, Nikolinka, additional, Antonova-Koch, Yevgeniya, additional, Appel, Jon R., additional, Arik, Anam J., additional, Arter, Alison L., additional, Arvan, Peter, additional, Ashkenazi, Avraham, additional, Baas, P.W., additional, Bado, André, additional, Baird, Andrew, additional, Baiula, Monica, additional, Bakaletz, Lauren O., additional, Bakken, Earl E., additional, Balaskó, Márta, additional, Baldwin, Graham S., additional, Banks, William A., additional, Barra, Donatella, additional, Barson, Jessica R., additional, Basille, Magali, additional, Bauer, Natalie N., additional, Bedini, Andrea, additional, Beeton, Christine, additional, Begley, David J., additional, Beinfeld, Margery C., additional, Bendena, William G., additional, Benoit, Stephen C., additional, Bentov, Itay, additional, Bern, Howard, additional, Bierbaum, Gabriele, additional, Billington, Charles J., additional, Blasiak, Anna, additional, Block, Norman L., additional, Bloom, Stephen. R., additional, Bonney, Iwona, additional, Bowie, John H., additional, Boyd, Sunny K., additional, Brain, Susan D., additional, Brede, Dag A., additional, Broeck, Jozef Vanden, additional, Brown, Kelly L., additional, Brown, Mark R., additional, Bugni, James M., additional, Bundgaard, Jens R., additional, Burel, Delphine, additional, Butenko, Melinka A., additional, Call, Melissa J., additional, Calò, Girolamo, additional, Campbell, Duncan John, additional, Carlsson, Anna, additional, Carr, Daniel B., additional, Carraway, Robert E., additional, Carreira, Marcos C., additional, Casanueva, Felipe F., additional, Cassella, Sarah N., additional, Casson, Stuart A., additional, Castaño, Justo P., additional, Cebrat, Marek, additional, Chappe, Valerie, additional, Chatenet, David, additional, Chen, Keqiang, additional, Chen, Chen, additional, Chen, Longchuan, additional, Chen, Duan, additional, Cheng, Carrie Y.Y., additional, Cho, Sung Ki, additional, Chow, Billy K.C., additional, Christopoulos, Arthur, additional, Chu, Shijian, additional, Clarke, Iain J., additional, Coast, Geoffrey M., additional, Compere, Vincent, additional, Concepcion, Gisela P., additional, Cone, Roger D., additional, Conlon, J. Michael, additional, Cornélissen, Germaine, additional, Courel, Maité, additional, Couture, Réjean, additional, Cramer, W.A., additional, Croft, Nathan P., additional, Crujeiras, Ana B., additional, Cuttitta, Frank, additional, Cynis, Holger, additional, D’Acquisto, F., additional, Davis, Jon F., additional, Davis, Thomas P., additional, de La Serre, Claire Barbier, additional, de Lartigue, Guillaume, additional, de Lecea, Luis, additional, de Oliveira Santos, Marcelo, additional, De Waard, Michel, additional, Bolette Hartmann, Carolyn F. Deacon, additional, Delestre, Charlène, additional, Delgado, Mario, additional, Demuth, Hans-Ulrich, additional, Deng, Xiaoming, additional, Dharmawardhana, Palitha, additional, Di Cosmo, Anna, additional, Dias, Simoni Campos, additional, Dickerson, Jonathan W., additional, Diep, Dzung B., additional, Dircksen, H., additional, Dischinger, Jasmin, additional, do Rego, Jean-Claude, additional, Dobner, Paul R., additional, Dockray, Graham J., additional, Dores, Robert M., additional, Ducroc, Robert, additional, Dudek, Nadine L., additional, Dumont, Yvan, additional, Duraffourd, Celine, additional, Duterte-Boucher, Dominique, additional, Eberlé, Alex N., additional, Egleton, Richard D., additional, Eipper, Betty A., additional, Engel, Jorg B., additional, Englander, Ella W., additional, Epelbaum, Jacques, additional, Erlanson-Albertsson, Charlotte, additional, Evangelista, S., additional, Fagan, Karen A., additional, Farber, Joshua M., additional, Farkasfalvi, Klára, additional, Fekete, Csaba, additional, Flatt, Peter R., additional, Flower, R.J., additional, Forssmann, Wolf-Georg, additional, Fournier, Alain, additional, Foy, Kevin Chu, additional, Franco, Octávio Luiz, additional, Frenkel, Dan, additional, Fricker, Lloyd D., additional, de la Fuente-Núñez, César, additional, Fukuda, Hiroo, additional, Gäde, Gerd, additional, Galas, Ludovic, additional, Gallagher, Patricia E., additional, Gandolfo, Pierrick, additional, Garcia-Espinosa, Maria A., additional, García-Sanmartín, Josune, additional, Geary, Nori, additional, Geng, Hua, additional, Germano, Patrizia M., additional, Goetze, Jens P., additional, Gonzalez, Alexis A., additional, Gonzalez, Ana, additional, Gosnell, Blake A., additional, Goto, Katsutoshi, additional, Gourcerol, Guillaume, additional, Gozes, I., additional, Gracia-Navarro, Francisco, additional, Grayson, Bernadette E., additional, Greeley, George H., additional, Greenwald-Yarnell, Megan, additional, Gressens, Pierre, additional, Grider, John R., additional, Grünewald, Jan, additional, Guerreiro, Juliano R., additional, Guerrini, Remo, additional, Guida, Filomena, additional, Guilhaudis, Laure, additional, Guilmeau, Sandra, additional, Gundlach, Andrew L., additional, Gutkowska, Jolanta, additional, Hackbarth, Clifton, additional, Haim Ohana, Y., additional, Halberg, Franz, additional, Hallberg, Mathias, additional, Hamidi, Sayyed A., additional, Han, Song, additional, Han, Ji-Sheng, additional, Hancock, Robert E.W., additional, Haque, Samer-ul, additional, Hara-Nishimura, Ikuko, additional, Hariton, Aliza, additional, Hartsock, Wendy J., additional, Harvey, Alan L., additional, Hasunuma, Itaru, additional, Henning, Robert J., additional, Heppner, Kristy M., additional, Hertweck, Kate L., additional, Herzog, Herbert, additional, Higashiyama, Tetsuya, additional, Hinuma, Shuji, additional, Hippenstiel, Stefan, additional, Hirakawa, Yuki, additional, Hirose, Shuichi, additional, Hirsch, Jochen R., additional, Hocke, Andreas C., additional, Hodges, Robert S., additional, Hoffmann, Werner, additional, Hökfelt, Tomas, additional, Holst, Jens Juul, additional, Holzer, Peter, additional, Horodyski, Frank M., additional, Hosoda, Hiroshi, additional, Hou, Xiaowen, additional, Huffaker, Alisa, additional, Iijima, Norio, additional, Ikeuchi, Momoko, additional, Imperial, Julita S., additional, Improta, Giovanna, additional, Inui, Akio, additional, Irwin, Nigel, additional, Ishii, Munehiro, additional, Iturrioz, Xavier, additional, Ivanisevic, Ljubica, additional, Iwao, Hiroshi, additional, Iwata, Takeo, additional, Izumi, Yasukatsu, additional, Izumiyama, Hajime, additional, Jankowski, Marek, additional, Janssen, Tom, additional, Jégou, Sylvie, additional, Jensen, Robert T., additional, Jethwa, Preeti H., additional, Johannessen, Helene, additional, Johanson, Conrad, additional, Judkowski, Valeria, additional, Kaczmarek, Przemyslaw, additional, Kageyama, Haruaki, additional, Kakimoto, Tatsuo, additional, Kang, Ki Sung, additional, Kangawa, Kenji, additional, Kastin, Abba J., additional, Kato, Johji, additional, Kaumaya, Pravin T.P., additional, Keep, Richard F., additional, Kem, William R., additional, Khomenko, Tetyana, additional, Kikuyama, Sakae, additional, Kim, Young-Joon, additional, Kimura, Sadao, additional, King, Ross, additional, Kiptoo, Paul, additional, Kishimoto, Ichiro, additional, Kitamura, Kazuo, additional, Kluczyk, Alicja, additional, Kobori, Hiroyuki, additional, Kodama, Yosuke, additional, Kojima, Masayasu, additional, Kondo, Yuki, additional, Körner, Meike, additional, Kosson, Piotr, additional, Kotz, Catherine M., additional, Krishnan, Bhavani, additional, Kulseng, Bård, additional, Kumpf, Robert, additional, Laburthe, Marc, additional, Lacaille, Hélène, additional, Ladenheim, Ellen E., additional, Ladram, Ali, additional, Laksitorini, Marlyn D., additional, Lambert, David G., additional, Lange, Angela B., additional, Langhans, Wolfgang, additional, Larauche, Muriel, additional, Larhammar, Dan, additional, Larráyoz, Ignacio M., additional, Lattanzi, Roberta, additional, Lechan, Ronald M., additional, Lefranc, Benjamin, additional, Leibowitz, Sarah F., additional, Lelièvre, Vincent, additional, Leprince, Jérôme, additional, Levine, Allen S., additional, Li, Qun, additional, Lifshitz, Veronica, additional, Lihrmann, Isabelle, additional, Chi-Jen Lin, James, additional, Lindberg, Iris, additional, Lindsey, Keith, additional, Lipkowski, Andrzej W., additional, Liron, T., additional, Liu, Junli, additional, Liu, Ying, additional, Liu, Min, additional, Llorens-Cortes, Catherine, additional, Loizidou, Marilena, additional, Lopez, C., additional, Lovejoy, David A., additional, Luca, Vincenzo, additional, Lutz, Thomas A., additional, Ma, Sherie, additional, Mains, Richard E., additional, Malagon, Maria M., additional, Malendowicz, Ludwik K., additional, Wan, Jennifer Man-Fan, additional, Mangoni, Maria Luisa, additional, Manigrasso, Michaele B, additional, Marahiel, Mohamed A., additional, Marco, Heather G., additional, Maric-Bilkan, Christine, additional, Marks, Nikki J., additional, Martin, Roland, additional, Martinez, Vicente, additional, Martínez, Alfredo, additional, Martinez-Fuentes, Antonio J., additional, Masler, Edward P., additional, Matsubayashi, Yoshikatsu, additional, Mattu, Harman S., additional, Maule, Aaron G., additional, McLaughlin, Patricia J., additional, McMurtry, Ivan F., additional, Meelkop, Ellen, additional, Mehdi, Saher, additional, Melchiorri, Pietro, additional, Millar, R.P., additional, Miller, Laurence J., additional, Miller, Miles, additional, Million, Mulugeta, additional, Minamino, Naoto, additional, Mittelman, M., additional, Miyauchi, Takashi, additional, Miyazato, Mikiya, additional, Mizoguchi, Hirokazu, additional, Mohme, Malte, additional, Montero-Hadjadje, Maité, additional, Moody, Terry W., additional, Mookherjee, Neeloffer, additional, Moran, Timothy H., additional, Morganstern, Irene, additional, Mori, Masatomo, additional, Morin, Fabrice, additional, Morris, John F., additional, Moura, Daniel S., additional, Mudge, Anna J., additional, Mul, Joram D., additional, Murthy, Karnam S., additional, Myers, Martin G., additional, Nachman, Ronald J., additional, Nahon, Jean-Louis, additional, Naithani, Sushma, additional, Nakada, Tomoaki, additional, Nakamachi, Tomoya, additional, Nakamura, Yuki, additional, Nalivaeva, Natalia N., additional, Nasrallah, June B., additional, Nässel, Dick R., additional, Navar, L. Gabriel, additional, Neelakantan, Pratap, additional, Negri, Lucia, additional, Nes, Ingolf F., additional, Neumann, D., additional, Neveu, Cindy, additional, Ng, Tzi Bun, additional, Ng, Stephanie Y.L., additional, Nicholson, Graham M., additional, Nicolas, Pierre, additional, Nishikimi, Toshio, additional, Nishiyama, Mariko, additional, Nogueiras, Rubén, additional, Norton, Raymond S., additional, Novotny, Laura A., additional, Nowak, Krzysztof W., additional, Nyberg, Fred, additional, Ochoa-Callejero, Laura, additional, Ove Ögren, Sven, additional, Ohgusu, Hideko, additional, Oh-I, Shinsuke, additional, Ojo, Opeolu O., additional, Olivera, Baldomero M., additional, Olucha-Bordonau, Francisco E., additional, Oppenheim, Joost J., additional, Orchard, Ian, additional, Ouellette, André J., additional, Pacheco-López, Gustavo, additional, Page, Nigel M., additional, Palma, Mario Sergio, additional, Pan, Weihong, additional, Park, Yoonseong, additional, Parmentier, Marc, additional, Passemard, Sandrine, additional, Patterson, Michael, additional, Paunovic, Brankica, additional, Pearce, Gregory, additional, Pedersen, Jens, additional, Peeters, Theo L., additional, Eugene Pekary, A., additional, Pelletier, Georges, additional, Perboni, Simona, additional, Pérez-Tilve, Diego, additional, Perjés, Ábel, additional, Perretti, M., additional, Pétervári, Erika, additional, Pinilla, Clemencia, additional, Pinskim, Jacek, additional, Pisegna, Joseph R., additional, Plankensteiner, Kristof, additional, Podvin, Sonia, additional, Poitras, Pierre, additional, Polese, Gianluca, additional, Pollock, David M., additional, Porto, William Farias, additional, Possani, Lourival D., additional, Pothoulakis, Charalabos, additional, Presse, Françoise, additional, Prieto, Minolfa C., additional, Prutchi-Sagiv, S., additional, Purcell, Anthony W., additional, Purtell, Louise, additional, Quirion, Rémi, additional, Rabat, Catalina Abad, additional, Rademaker, Miriam, additional, Rajpal, Gautam, additional, Randeva, Harpal S., additional, Rebuffat, Sylvie, additional, Reeve, Joseph R., additional, Rehfeld, Jens F., additional, Reinhold, Dirk, additional, Reinscheid, Rainer K., additional, Reubi, Jean Claude, additional, Rezvani, Katayoun, additional, Ribeiro, Suzana Meira, additional, Richard, D., additional, Richards, Mark, additional, Riehle, Michael A., additional, Rinaldi, Andrea C., additional, Rode, Bernd M., additional, de la Vega, Ricardo C. Rodríguez, additional, Rotzinger, Susan, additional, Rucinski, Marcin, additional, Ruskoaho, Heikki, additional, Ryan, Philip J., additional, Sabatier, Jean-Marc, additional, Sahl, Hans-Georg, additional, Said, Sami I., additional, Sakurada, Tsukasa, additional, Sakurada, Shinobu, additional, Salomon, David S., additional, Samson, Willis K., additional, Sandor, Zsuzsanna, additional, Saragovi, H. Uri, additional, Sasaki, Kazuki, additional, Sato, Takahiro, additional, Satou, Ryousuke, additional, Sawa, Shinichiro, additional, Sayegh, Ayman I., additional, Schally, Andrew V., additional, Schilling, Stephan, additional, Schoofs, Liliane, additional, Schooley, David A., additional, Schubert, Mitchell L., additional, Segalas-Milazzo, Isabelle, additional, Seidah, Nabil G., additional, Selsted, Michael E., additional, Seroogy, Kim B., additional, Severini, Cinzia, additional, Sexton, Patrick M., additional, Shai, Yechiel, additional, Sharma, O., additional, Shichiri, Masayoshi, additional, Shimada, Tomoo, additional, Shimizu, Hiroyuki, additional, Shioda, Seiji, additional, Shulkes, Arthur, additional, Siahaan, Teruna J., additional, Siemion, Ignacy Z., additional, Silva, Osmar Nascimento, additional, Silva-Filho, Marcio C., additional, Skwarczynski, Mariusz, additional, Small, Caroline. J., additional, Smith, Craig M., additional, Smith, David E., additional, Smith, A. Ian, additional, Solomon, Beka, additional, Solomon, Travis E., additional, Sospedra, Mireia, additional, Souroujon, M.C., additional, Spampinato, Santi, additional, Spindel, Eliot R., additional, Steiger, A., additional, Stengel, Andreas, additional, Sternini, Catia, additional, Steyn, Frederik J., additional, Stopa, Edward, additional, Strowski, Mathias Z., additional, Sugano, Shigeo S., additional, Sundström, Görel, additional, Sutcliffe, J. Gregor, additional, Suttorp, Norbert, additional, Sweedler, Jonathan V., additional, Szabo, Sandor, additional, Székely, Miklós, additional, Szokodi, István, additional, Taché, Yvette, additional, Takahashi, Kazuhiro, additional, Takei, Yoshio, additional, Takenoya, Fumiko, additional, Talbot, Sébastien, additional, Tallant, E. Ann, additional, Tan, Tricia M., additional, Temmerman, Liesbet, additional, Temmesfeld-Wollbrück, Bettina, additional, Tena-Sempere, Manuel, additional, Thorsell, Annika, additional, Tilakaratne, Nanda, additional, Tobe, Stephen S., additional, Tokudome, Takeshi, additional, Tolstanova, Ganna, additional, Tonon, Marie-Christine, additional, Topping, Jennifer F., additional, Tossi, Alessandro, additional, Tostivint, Hervé, additional, Toth, Istvan, additional, Totsune, Kazuhito, additional, Toyoda, Fumiyo, additional, Troke, Rachel, additional, Tschöp, Matthias H., additional, Tso, Patrick, additional, Tsukaya, Hirokazu, additional, Tsutsui, Kazuyoshi, additional, Tu, Hong, additional, Turner, Anthony J., additional, Ubuka, Takayoshi, additional, Valdivia, Elene R., additional, Vandersmissen, Hans Peter, additional, Vaudry, David, additional, Vaudry, Hubert, additional, Vazquez-Martinez, Rafael, additional, Verbalis, Joseph G., additional, Vicari, Daniele, additional, Vidal, Nicolas, additional, Vignoni, Marzia, additional, Viollet, Cécile, additional, Vishwanatha, K.S., additional, Vivoli, Mirella, additional, Voisin, Thierry, additional, Vu, John P., additional, Walker, John C., additional, Wallace, B.A., additional, Wang, Ji Ming, additional, Wang, Lixin, additional, Wardman, Jonathan H., additional, Watanabe, Takuya, additional, Welch, Hazel, additional, Werner, Haim, additional, Whitmore, L., additional, Wiedemann, Imke, additional, Winsky-Sommerer, Raphaelle, additional, Witt, Ken A., additional, Wojciechowicz, Tatiana, additional, Wong, Jack Ho, additional, Woods, Stephen C., additional, Wootten, Denise, additional, Wu, Vincent, additional, Wurtz, Olivier, additional, Xiong, Ximing, additional, David Xu, Zhi-Qing, additional, Yamaguchi, Yube, additional, Yamaguchi, Takahiro, additional, Yamamoto, Kazutoshi, additional, Yamashita, E., additional, Yamazaki, Hiroyuki, additional, Yang, De, additional, Yoshikawa, Masaaki, additional, Yuan, Pu-Qing, additional, Yung, Sunny C., additional, Zagon, Ian S., additional, Zakharov, S.D., additional, Zaman, Mehfuz, additional, Zhalnina, M.V., additional, Zhang, Ning, additional, Zhang-Auberson, Lixin, additional, Zhao, Chun-Mei, additional, Ziolkowska, Agnieszka, additional, and Zitnan, Dusan, additional
- Published
- 2013
- Full Text
- View/download PDF
45. Drosophila target of rapamycin kinase functions as a multimer
- Author
-
Zhang, Yong, Billington, Charles J., Jr., Pan, Duojia, and Neufeld, Thomas P.
- Subjects
Drosophila -- Genetic aspects ,Drosophila -- Research ,Gene mutations -- Research ,Protein kinases -- Research ,Biological sciences - Abstract
Target of rapamycin (TOR) is a conserved regulator of cell growth and metabolism that integrates energy, growth factor, and nutrient signals. The 280-kDa TOR protein functions as the catalytic component of two large multiprotein complexes and consists of an N-terminal HEAT-repeat domain and a C-terminal Ser/Thr kinase domain. Here we describe an allelic series of mutations in the Drosophila Tor gene and show that combinations of mutations in the HEAT and kinase domains of TOR display the rare genetic phenomenon of intragenic complementation, in which two or more defective proteins assemble to form a functional multimer. We present biochemical evidence that TOR self-associates in vivo and show that this multimerization is unaffected by positive or negative signals upstream of TOR. Consistent with multimerization of TOR, recessive mutations in the HEAT and kinase domains can dominantly interfere with wild-type TOR function in cells lacking TSC1 or TSC2. TOR multimerization thus partially accounts for the high apparent molecular weight of TOR complexes and offers novel therapeutic strategies for pathologies stemming from TOR hyperactivity.
- Published
- 2006
46. Roux-en-Y Gastric Bypass vs Intensive Medical Management for the Control of Type 2 Diabetes, Hypertension, and Hyperlipidemia: The Diabetes Surgery Study Randomized Clinical Trial
- Author
-
Ikramuddin, Sayeed, Korner, Judith, Lee, Wei-Jei, Connett, John E., Inabnet, William B., III, Billington, Charles J., Thomas, Avis J., Leslie, Daniel B., Chong, Keong, Jeffery, Robert W., Ahmed, Leaque, Vella, Adrian, Chuang, Lee-Ming, Bessler, Marc, Sarr, Michael G., Swain, James M., Laqua, Patricia, Jensen, Michael D., and Bantle, John P.
- Published
- 2013
- Full Text
- View/download PDF
47. Maternal Diet Supplementation with Methyl Donors and Increased Parity Affect the Incidence of Craniofacial Defects in the Offspring of Twisted gastrulation Mutant Mice1-3
- Author
-
Billington, Charles J., Jr, Schmidt, Brian, Zhang, Lei, Hodges, James S., Georgieff, Michael K., Schotta, Gunnar, Gopalakrishnan, Rajaram, and Petryk, Anna
- Published
- 2013
- Full Text
- View/download PDF
48. Neuropeptides Controlling Energy Balance: Orexins and Neuromedins
- Author
-
Nixon, Joshua P., primary, Kotz, Catherine M., additional, Novak, Colleen M., additional, Billington, Charles J., additional, and Teske, Jennifer A., additional
- Published
- 2011
- Full Text
- View/download PDF
49. Peptides that regulate food intake: effects of the opioid antagonist naltrexone on feeding induced by DAMGO in the ventral tegmental area and in the nucleus accumbens shell region in the rat
- Author
-
MacDonald, Amy F., Billington, Charles J., and Levine, Allen S.
- Subjects
Peptides -- Research ,Biological sciences - Abstract
MacDonald, Amy F., Charles J. Billington, and Allen S. Levine. Effects of the opioid antagonist naltrexone on feeding induced by DAMGO in the ventral tegmental area and in the nucleus accumbens shell region in the rat. Am J Physiol Regul Integr Comp Physiol 285: R999-R1004, 2003. First published August 7, 2003; 10.1152/ajpregu.00271. 2003.--The nucleus accumbens shell region (sNAcc) and the ventral tegmental area (VTA) are two major nodes in the mesolimbic dopamine pathway, which mediates reward for various survival behaviors, including feeding. Opioids increase and maintain food intake when injected peripherally and centrally. Opioids in the VTA cause increased release of dopamine in the sNAcc, and when injected into either site, cause an increase in food intake. Animals in this study were double cannulated in the VTA and in the sNAcc and injected with various combinations of naltrexone (NTX) (2.5, 5, and 25 [micro]g/side) and Tyr-D-Ala-Gly-(Me)Phe-Gly-ol (DAMGO) (0.1, 0.3, 1, 3, and 5 nmol/side) in both sites. DAMGO was found to dose dependently increase intake to an equal extent when injected into either site. DAMGO-induced increases in food intake when injected into the VTA were blocked to control levels with the highest dose of NTX injected bilaterally into the sNAcc; however, increases in intake when injected into the sNAcc were blocked only partially by the highest dose of NTX injected bilaterally into the VTA. These results indicate opioid-opioid communication between the two sites; however, the communication may be quite indirect, requiring other sites and transmitters to elicit a change in behavior. food intake; mesolimbic; microinjection; reward
- Published
- 2003
50. Naltrexone infusion inhibits the development of preference for a high-sucrose diet
- Author
-
Levine, Allen S., Grace, Martha K., Cleary, James P., and Billington, Charles J.
- Subjects
Naltrexone -- Research ,Opioids -- Research ,Biological sciences - Abstract
We hypothesized that the opioid antagonist naltrex-one would inhibit the redevelopment of a preference for a high-sucrose diet after an abstention period from this diet. Rats that chose between a starch or sucrose diet for 10 days preferred the sucrose diet. Rats were then given access to the starch diet alone for another 10-day period. A miniosmotic pump containing saline or naltrexone was then implanted (70 [micro]g/h; 1.7 mg/day) for ~10 days. During the saline infusion, 77% of the total energy came from the sucrose diet, whereas during the naltrexone infusion, 33% of the total energy came from the sucrose diet. We repeated this study in another group of rats but did not restrict the sucrose diet. In this case naltrexone failed to decrease preference for the sucrose diet. Thus naltrexone infusion inhibited redevelopment of a preference for a sucrose diet after a period of restriction to a starch diet for 10 days but had no effect on preference if both diets were present throughout the study. opioids; reward; food intake; satiety; learning
- Published
- 2002
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.